| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6265536 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Sep, 2015
(8 years ago) | |
| US6107458 | ASTELLAS | Cyclic hexapeptides having antibiotic activity |
Mar, 2019
(5 years ago) | |
| US6774104 | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jan, 2021
(3 years ago) | |
|
US6774104 (Pediatric) | ASTELLAS | Stabilized pharmaceutical composition in lyophilized form |
Jul, 2021
(2 years ago) | |
Mycamine is owned by Astellas.
Mycamine contains Micafungin Sodium.
Mycamine has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Mycamine are:
- US6265536
- US6107458
- US6774104
- US6774104*PED
Mycamine was authorised for market use on 16 March, 2005.
Mycamine is available in injectable;intravenous dosage forms.
Mycamine can be used as treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses, treatment of esophageal candidiasis and prophylaxis of candida infections in hsct patients.
The generics of Mycamine are possible to be released after 20 June, 2023.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Pediatric Exclusivity(PED) | Jun 20, 2023 |
| New Indication(I-821) | Dec 20, 2022 |
Drugs and Companies using MICAFUNGIN SODIUM ingredient
Market Authorisation Date: 16 March, 2005
Treatment: Treatment of esophageal candidiasis and prophylaxis of candida infections in hsct patients; Treatment of patients with candidemia, acute disseminated candidiasis, candida peritonitis and abscesses
Dosage: INJECTABLE;INTRAVENOUS
MYCAMINE family patents
